100 related articles for article (PubMed ID: 12042985)
1. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
Löhr M; Hummel F; Faulmann G; Ringel J; Saller R; Hain J; Günzburg WH; Salmons B
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S21-4. PubMed ID: 12042985
[TBL] [Abstract][Full Text] [Related]
2. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
Salmons B; Löhr M; Günzburg WH
J Gastroenterol; 2003 Mar; 38 Suppl 15():78-84. PubMed ID: 12698877
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
[TBL] [Abstract][Full Text] [Related]
4. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Günzburg WH; Salmons B
Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial instillation of microencapsulated, Ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting.
Kröger JC; Benz S; Hoffmeyer A; Bago Z; Bergmeister H; Günzburg WH; Karle P; Klöppel G; Losert U; Müller P; Nizze H; Obermaier R; Probst A; Renner M; Saller R; Salmons B; Schwendenwein I; von Rombs K; Wiessner R; Wagner T; Hauenstein K; Löhr M
Pancreatology; 2003; 3(1):55-63. PubMed ID: 12649565
[TBL] [Abstract][Full Text] [Related]
7. Small agarose microcapsules with cell-enclosing hollow core for cell therapy: transplantation of Ifosfamide-activating cells to the mice with preestablished subcutaneous tumor.
Sakai S; Hashimoto I; Tanaka S; Salmons B; Kawakami K
Cell Transplant; 2009; 18(8):933-9. PubMed ID: 19500478
[TBL] [Abstract][Full Text] [Related]
8. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
[TBL] [Abstract][Full Text] [Related]
9. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Karle P; Renner M; Salmons B; Günzburg WH
Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.
Ryschich E; Jesnowski R; Ringel J; Harms W; Fabian OV; Saller R; Schrewe M; Engel A; Schmidt J; Löhr M
Int J Cancer; 2005 Feb; 113(4):649-53. PubMed ID: 15455374
[TBL] [Abstract][Full Text] [Related]
13. [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
Fujiki T; Futatsuki K; Akazawa S; Yamamoto K; Kanda Y; Yamato A; Terashi K; Suda Y
Gan To Kagaku Ryoho; 1997 Mar; 24(5):569-72. PubMed ID: 9087289
[TBL] [Abstract][Full Text] [Related]
14. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
Samel S; Löhr M
Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
[TBL] [Abstract][Full Text] [Related]
15. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
[TBL] [Abstract][Full Text] [Related]
16. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
[TBL] [Abstract][Full Text] [Related]
17. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
18. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
19. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
Duan X; Jia SF; Koshkina N; Kleinerman ES
Cancer; 2006 Mar; 106(6):1382-8. PubMed ID: 16453328
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
Liu JP; Yuan SZ; Zhang SN
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
